OBJECTIVE: Massive parallel sequencing (MPS) is the new frontier for molecular diagnostics. Twenty-four papers regarding BRCA analysis were considered for reviewing all pipelines evaluated in this field. METHODS: Proposed here is an integrated MPS workflow able to successfully identify BRCA1/2 mutational status on 212 Italian ovarian cancer patients. The review of literature data is reported. RESULT: The pipeline can be routinely used as robust molecular diagnostic strategy, being highly sensitive and specific. CONCLUSION: Literature data report that efforts are being made in order to fully translate MPS-based BRCA1/2 gene assay into routine clinical diagnostics. However, this study highlights the need of an integrated MPS BRCA1/2 molecular workflow fulfilling the standardized requirements needed in the routine clinical laboratory practice.
OBJECTIVE: Massive parallel sequencing (MPS) is the new frontier for molecular diagnostics. Twenty-four papers regarding BRCA analysis were considered for reviewing all pipelines evaluated in this field. METHODS: Proposed here is an integrated MPS workflow able to successfully identify BRCA1/2 mutational status on 212 Italian ovarian cancerpatients. The review of literature data is reported. RESULT: The pipeline can be routinely used as robust molecular diagnostic strategy, being highly sensitive and specific. CONCLUSION: Literature data report that efforts are being made in order to fully translate MPS-based BRCA1/2 gene assay into routine clinical diagnostics. However, this study highlights the need of an integrated MPSBRCA1/2 molecular workflow fulfilling the standardized requirements needed in the routine clinical laboratory practice.
Entities:
Keywords:
BRCA1/2 genes; bioinformatics NGS analysis; hereditary breast and ovarian cancer syndrome; massive parallel sequencing; next-generation sequencing
Authors: Angelo Minucci; Giorgia Mazzuccato; Marco D'Indinosante; Lucia Di Nardo; Paola Concolino; Maria De Bonis; Andrea Urbani; Giovanni Scambia; Anna Fagotti; Ettore Capoluongo Journal: Mol Biol Rep Date: 2019-12-12 Impact factor: 2.316
Authors: Maria De Bonis; Angelo Minucci; Giovanni Luca Scaglione; Elisa De Paolis; Gianfranco Zannoni; Giovanni Scambia; Ettore Capoluongo Journal: Fam Cancer Date: 2019-01 Impact factor: 2.375
Authors: Giovanni Luca Scaglione; Paola Concolino; Maria De Bonis; Elisa De Paolis; Angelo Minucci; Gabriella Ferrandina; Giovanni Scambia; Ettore Capoluongo Journal: Int J Mol Sci Date: 2018-03-23 Impact factor: 5.923
Authors: Alessandra Costella; Rossella De Leo; Donatella Guarino; Marco D'Indinosante; Paola Concolino; Giorgia Mazzuccato; Andrea Urbani; Giovanni Scambia; Ettore Capoluongo; Anna Fagotti; Angelo Minucci Journal: Hum Genome Var Date: 2018-06-08